Somatostatin inhibits insulin release via SSTR2 in the hamster pancreatic islets

Date
2004-01-01
Authors
Yao, Cheng-Yu
Major Professor
Advisor
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
Altmetrics
Authors
Research Projects
Organizational Units
Animal Science
Organizational Unit
Journal Issue
Series
Department
Animal Science
Abstract

It is generally accepted that somatostatin receptor subtype 5 (SSTR5) mediates the inhibition of insulin release. This is due to the fact that in the human, rat, and mouse somatostatin (SST) inhibits insulin release via SSTR5; however, in a preliminary study from Dr. Hsu's laboratory with HIT-T15 [beta]-cells that are derived from hamster insulinoma, it was found that a SSTR2 agonist, but not other SSTR agonists, inhibited insulin release. Since SSTR2 is highly expressed in tumor cells, it is possible that the results from HIT-T15 cells may be due to the nature of tumor cells. Thus, it is hypothesized that in hamsters, SSTR2 mediates somatostatin-induced inhibition of insulin release. Isolated hamster pancreatic islets were used in the present study to test this hypothesis. Both somatostatin (1-100 nM) and nonpeptide SSTR2 agonist L-779,976 (0.1-100 nM) inhibited insulin release in a dose-dependent manner. Nonpeptide agonists for SSTR1, 3, 4, and 5 at the highest concentration studied (1[mu]M) failed to inhibit insulin release. PRL-2903, a peptide SSTR2 antagonist (0.3-1[mu]M), antagonized somatostatin-induced inhibition of insulin release in a dose-dependent manner. It is concluded that in hamster [beta]-cells, somatostatin inhibits insulin release via SSTR2 but not SSTR5.

Comments
Description
Keywords
Citation
Source